01 Shift toward Dedicated Radiopharmaceutical Manufacturing NetworksThe radioligand therapy market analysis shows that the need for reliable isotope supplies and time-sensitive radioactive drug delivery is shifting manufacturers toward dedicated production facilities and specialized distribution networks. Novartis announced that its Indianapolis radioligand therapy manufacturing facility was designed to increase Pluvicto production capacity to 250,000 doses annually.
02 New Molecular Targets Beyond Prostate CancerResearch into tumor-specific biomarkers is broadening radioligand therapy development beyond established applications in prostate and neuroendocrine cancers. Scientists are investigating targets such as fibroblast activation protein (FAP) and gastrin-releasing peptide receptors (GRPR) to identify new ways of delivering radiation directly to tumor cells across different cancer types.
01 The radioligand therapy market forecasts capital used for clinical-stage drug development, isotope supply security and specialised manufacturing capacity.
02 Key Investment and Funding Activities in Radioligand Therapy Market, 2026CompanyValue (USD)DetailsProtheriumUSD 17.5 MillionIn September 2026, Protherium secured financing through equity, bank loans and public subsidies to develop radiopharmaceutical manufacturing facilities in Nancy, France, and prepare expansion into Belgium and Germany. The investment supports manufacturing infrastructure for radiopharmaceutical therapies, including radioligand treatments.Ratio TherapeuticsUSD 70 MillionIn July 2026, Ratio Therapeutics raised Series C funding to advance its radiotherapeutic pipeline, including its lead actinium-225 candidate for advanced sarcomas, and progress another radioligand therapy into clinical development. Investors included Bristol Myers Squibb and Eli Lilly.AdvanCellUSD 315 MillionIn July 2026, AdvanCell closed an oversubscribed Series D financing to advance ADVC001, a lead-212 PSMA-targeted radioligand therapy for metastatic prostate cancer, toward Phase III development. The funding will also expand radiopharmaceutical manufacturing and isotope supply capabilities.Starget PharmaUSD 18 MillionIn February 2026, Starget Pharma raised Series A funding to advance its next-generation peptide radioligand therapy pipeline for cancer. The financing will support AI-enabled radioligand discovery, clinical development and expansion of its U.S. operations and manufacturing capabilities.
01 Expansion of PSMA-Based Prostate Cancer Treatment Drives MarketDemand for radioligand therapy is supported by the use of prostate-specific membrane antigen (PSMA) as a molecular target in advanced prostate cancer, particularly among patients whose disease has progressed despite other treatments. PSMA-targeted therapies enable clinicians to deliver radiation directly to cancer cells expressing this protein, expanding treatment options for eligible patients. For example, Novartis' Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is approved for eligible adults with PSMA-positive metastatic castration-resistant prostate cancer.
02 Dependence on Precision Oncology Treatment Programs Strengthens Radioligand Therapy Market DemandPrecision oncology programs use molecular imaging and biomarker testing to identify patients whose tumors express specific treatment targets. This creates demand for radiopharmaceuticals alongside diagnostic imaging procedures that determine patient eligibility and guide treatment selection. Advanced Accelerator Applications' Lutathera (lutetium Lu 177 dotatate) is used to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, with receptor expression assessed through diagnostic imaging.
03 Impact Analysis of Key Drivers in Radioligand Therapy MarketDriversMarket ImpactExpansion of PSMA-Based Prostate Cancer TreatmentThe use of prostate-specific membrane antigen (PSMA) as a molecular target is supporting radioligand therapy adoption among patients with advanced prostate cancer, particularly those with limited treatment options.Dependence on Precision Oncology Treatment ProgramsPrecision oncology programs encourage healthcare providers to adopt radioligand therapies for eligible cancer patients based on specific molecular targets, expanding clinical use in specialized cancer treatment.Use of Theranostic Treatment ApproachesHealthcare providers are adopting paired diagnostic imaging and therapeutic radiopharmaceuticals to identify suitable patients, assess target expression, and guide treatment selection.Advancements in Alpha-Emitting RadioisotopeResearch into alpha-emitting isotopes such as actinium-225 and lead-212 is supporting the development of radioligand therapies with high-energy, short-range radiation designed to damage cancer cells.Clinical Evidence for Radioligand Combination TherapiesClinical research evaluating radioligand therapies alongside immunotherapy, chemotherapy, and other targeted treatments is expanding their potential role in combination treatment regimens.
01 Limited Treatment Infrastructure and Specialized Facilities Restrain Market ExpansionLimited access to specialized treatment centers restricts the adoption of radioligand therapy, particularly in community hospitals and regions with fewer nuclear medicine services. According to the OECD Nuclear Energy Agency’s 2025 report, establishing a theranostic service can take one to five years, depending on existing infrastructure, staffing, and regulatory readiness. These requirements delay the expansion of treatment capacity and limit patient access to radioligand therapy.
02 High Treatment Costs Constrain Market GrowthHigh treatment costs, specialized imaging requirements, and expenses associated with radiation-safe facilities can place financial pressure on healthcare providers and patients. The U.S. Medicare fee schedule lists Pluvicto at USD 300.41 per millicurie from July 1, 2026, while the FDA-recommended dose is 200 millicuries every six weeks for up to six doses; this fee-schedule rate is not the total treatment cost. Such expenses can create reimbursement challenges and limit access, particularly in healthcare systems with restricted coverage for advanced cancer therapies.
03 Impact Analysis of Key Restraints in Radioligand Therapy MarketRestraintsMarket ImpactHigh Treatment CostsThe high costs of radioligand therapies, specialized equipment, and treatment delivery can limit patient access and create financial pressure on healthcare providers and reimbursement systems.Limited Availability of RadioisotopesDependence on specialized therapeutic radioisotopes, including lutetium-177 and actinium-225, creates supply constraints that can disrupt treatment schedules and limit the number of patients receiving therapy.Limited Treatment Infrastructure and Specialized FacilitiesRadioligand therapy requires radiation-handling facilities, specialized equipment, and trained nuclear medicine teams. Limited capacity at qualified treatment centers can delay patient access and restrict broader adoption.Complex Regulatory Approval and Radiation Safety RequirementsStrict requirements for radioactive materials, manufacturing quality, transportation, handling, and clinical use can increase compliance costs and complicate the introduction of new radioligand therapies across markets.Treatment-Related Side Effects and Patient Eligibility LimitationsPotential adverse effects, including bone marrow suppression and kidney toxicity for certain therapies, require careful patient selection and monitoring. These clinical considerations can limit treatment suitability and affect wider adoption.
01 Radioisotope Recycling and Recovery Technologies Expand Growth OpportunitiesRadioisotope producers, radiopharmaceutical manufacturers, and specialized nuclear technology companies can develop recovery processes to reclaim valuable radioactive materials from production waste and spent targets. This opens revenue avenues through isotope recovery services, material reuse, and supply agreements while helping manufacturers manage isotope procurement costs and material availability. For example, SHINE Technologies has developed recycling and recovery capabilities for molybdenum-99 production, including the recovery of uranium from its production process.
02 Development of Radioligand Therapy Combination Treatment Opens New Revenue AvenuesPharmaceutical companies and radiopharmaceutical developers can collaborate to evaluate radioligand therapies alongside immunotherapies, chemotherapy, and targeted drugs. Collaborative research agreements, clinical development partnerships, licensing arrangements, and expanded treatment indications open novel revenue streams. Successful combination studies can also strengthen the commercial potential of existing radioligand therapy portfolios.
September 2026 Curium Pharma received U.S. FDA approval for BEXLUTRY (lutetium Lu 177 dotatate) to treat adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
September 2026 Lantheus received final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent product to LUTATHERA for adults with GEP-NETs.
September 2026 Novartis and BoomRay Therapeutics entered a licensing agreement for a preclinical radioligand therapy candidate.
May 2026 Novartis began construction of a new 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas.
May 2026 Affibody dosed the first patient in Part B of its Phase 1 clinical study of ABY-271, a radioligand therapy candidate for HER2-positive metastatic breast cancer.
February 2026 Curium, PeptiDream, and PDRadiopharma dosed the first patient in a registrational Phase 2 trial of ¹⁷⁷Lu-PSMA-I&T in Japan for PSMA-positive metastatic castration-resistant prostate cancer.
January 2026 ARTBIO began dosing two patient cohorts in its Phase 1 ARTISAN trial of AB001, a lead-212 alpha radioligand therapy candidate for metastatic castration-resistant prostate cancer.